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Research in context  
An initial pubmed search was performed in December 2018 using the key words ‘MRI’, 
‘Survival’, ‘Paediatric brain tumour’, ‘Machine Learning’, ‘Diffusion’, and ‘Perfusion’. We 
found several studies using diffusion and perfusion weighted imaging to distinguish 
between high and low-grade brain tumours, and also between tumour types. Further 
evidence for assessing paediatric brain tumours with magnetic resonance spectroscopy 
were found, with two particularly focused on assessing survival with either glycine or 
tumour lipid production. However, no such studies assessing the use of diffusion and 
perfusion imaging in predicting survival in paediatric brain tumours was found. 
Furthermore, no studies utilising advanced machine learning algorithms to automatically 
assess and predict survival in paediatric brain tumours using medical imaging were found.  
 
Added value of this study  
This study provides a novel, non-invasive, framework for the early assessment of tumour 
risk, and therefore predicted survival, within the paediatric brain tumour population using 
multi-centre perfusion and diffusion weighted imaging. Combining imaging with advanced 
machine learning methods, elevated perfusion within a tumour (regardless of grade and 
histological subtype) was predictive of decreased survival probability, and when combined 
with diffusion imaging revealed a novel stratification of low-and high-risk tumours that bear 
dramatically altered survival characteristics. These sub-groups had a mix of both low- and 
high-grade tumours and contained a mixture of tumour types, and it was possible to 
automatically classify cases using supervised machine learning with high accuracy.  
 
Implications of all the available evidence  
The implications of our study are that the introduction of acquisition and interpretation of 
perfusion imaging at diagnosis plays a key role in the initial assessment of paediatric brain 
tumour risk. Furthermore, the assignment of new brain tumour cases to low or high-risk 
categories at diagnosis will allow for convectional therapy or recruitment to trails for 
experimental therapies to be undertaken, respectively.  
 
 
 
  
Abstract  
Background 
Brain tumours represent the highest cause of mortality in the paediatric oncological 
population. Diagnosis is commonly performed with magnetic resonance imaging and 
spectroscopy. Survival biomarkers are challenging to identify due to the relatively low 
numbers of individual tumour types, especially for rare tumour types such as atypical 
rhabdoid tumours.  
 
Methods 
69 children with biopsy-confirmed brain tumours were recruited into this study. All 
participants had both perfusion and diffusion weighted imaging performed at diagnosis. 
Data were processed using conventional methods, and a Bayesian survival analysis 
performed. Unsupervised and supervised machine learning were performed with the 
survival features, to determine novel sub-groups related to survival.  
Sub-group analysis was undertaken to understand differences in imaging features, which 
pertain to survival.  
 
Findings 
Survival analysis showed that a combination of diffusion and perfusion imaging were able to 
determine two novel sub-groups of brain tumours with different survival characteristics (p 
<0.01), which were subsequently classified with high accuracy (98%) by a neural network. 
Further analysis of high-grade tumours showed a marked difference in survival (p=0.029) 
between the two clusters with high risk and low risk imaging features. 
 
Interpretation 
This study has developed a novel model of survival for paediatric brain tumours, with an 
implementation ready for integration into clinical practice. Results show that tumour 
perfusion plays a key role in determining survival in brain tumours and should be considered 
as a high priority for future imaging protocols. 
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Introduction 
Brain tumours represent one of the most common causes of paediatric and adult 
oncological mortality. Particular challenges are faced in clinical paediatric oncology research 
due to the highly heterogeneous nature of paediatric tumours, combined with the relative 
rarity of the disease in the general population1. Despite this, multi-centre studies have 
allowed impressive advances to be made in the understanding of the major types of 
children’s brain tumours and these are starting to change clinical practice2,3. The majority of 
studies have relied on analysis of tumour tissue; however, medical imaging is becoming 
increasingly able to probe tissue properties and has the advantage that measurements are 
made directly in vivo. This is particularly important for probing the tissue microenvironment 
since quantities such as perfusion cannot be readily determined in tissue samples. Imaging 
therefore has the potential to provide new biomarkers of prognosis which can be obtained 
early and throughout the patient journey. 
 
Recently an increased understanding of paediatric brain tumour biology has enabled more 
accurate prognostication for individual patients. The findings have largely been based on 
molecular genetic markers identified in tissue. For example in  medulloblastoma, biological 
subgrouping has shown that WNT subgroup tumours have an excellent prognosis whereas 
group 3 tumours and subsets of SHH tumours have an inferior outcome4. However, in even 
rarer tumours, such as  atypical rhabdoid tumours (ATRT), or midline gliomas, where biopsy 
derived tissue is challenging to acquire, it is even more challenging to perform studies5. 
Therefore, biological studies have been more difficult to perform in meaningful numbers for 
many tumour types and the small biopsies taken may not provide a representative view of 
the tumour, particularly its microenvironment.  
 
Medical imaging is an important diagnostic aid for brain tumours, since it is non-invasive 
and can include the whole tumour and surrounding tissue. It is also capable of probing the 
tumour microenvironment in vivo, improving  our understanding of the in vivo 
neovascularisation and cellularity of the tumour, as well as surrounding cerebral tissue 
through perfusion and diffusion imaging, respectively6,7. However, as mentioned above for 
biological studies, recruiting large numbers of patients for imaging studies is challenging, 
and often requires large multi-centre trials to glean meaningful results. In spite of this, these 
non-invasive modalities represent highly attractive methods to derive crucial information 
surrounding the diagnosis and progression of tumours.  
  
Diffusion imaging is available on every major commercial MRI scanner and is routinely used 
to assess brain tumors8. Apparent diffusion coefficient (ADC) maps represent the speed of 
water motion in the tissue and this correlated cellularity. Perfusion imaging is often 
acquired either with dynamic susceptibility contrast (DSC) or arterial spin labelling (ASL) 
techniques9,10. DSC imaging is undertaken through the introduction of an exogeneous 
contrast agent containing gadolinium, and the passage of this bolus through the cerebral 
vasculature is rapidly imaged and post-processed to form quantitative cerebral blood 
volume and flow maps11. 
 
Studies have shown that diffusion and perfusion imaging are able to discriminate between 
paediatric tumour types in vivo, with high cellularity and perfusion in high grade tumours, 
and vice versa for low-grade12,13. This data, in turn, has informed survival analysis models 
using traditional methods such as Cox-regression to derive significant covariates from 
imaging data14. In particular,  ADC mean, elevated cerebral blood flow, and image derived 
texture parameters have been found to be significant factors in long-term paediatric brain 
tumour survival7,15,16. 
 
In this study we have taken a novel approach to the understanding of risk and survival in 
paediatric brain tumours. We have combined a cohort of patients with multiple tumour 
types, including both common and rare tumours, and grades from multiple clinical centres. 
All participants had both perfusion and diffusion imaging, we have employed both 
supervised and unsupervised machine learning to determine key imaging derived risk 
factors to further our understanding and prediction of survival in the paediatric 
neurooncological population.  
 
  
Methods 
 
Patient recruitment and imaging 
69 participants with suspected brain tumours (medulloblastoma (N = 17), pilocytic 
astrocytoma (N = 22), ependymoma (considered high grade, N = 10), other tumours (N = 20) 
are found in supplementary document 1. They were recruited from four clinical sites in the 
United Kingdom (Ethics reference: 04/MRE04/41, Birmingham Children’s Hospital, 
Newcastle Royal Victoria Infirmary, Queen’s Medical Centre, Alder Hey Children’s Hospital, 
Liverpool). Participants underwent MRI, protocol discussed below, before invasive biopsy to 
confirm diagnosis. The median follow-up time for the cohort was 4.4 years. Tumours were 
assigned to high- (3&4) and low-grade (1&2) groups, with full cohort details found in 
supplementary document 1.  
 
The imaging protocol for all participants was performed either at 3 or 1.5T and included 
standard anatomical imaging (T1-weighted pre- and post- contrast and T2-weighted) as well 
as diffusion and dynamic susceptibility contrast imaging covering the tumour volume 
(imaging sequence details found in supplementary Table 1). Additional clinical data (age at 
diagnosis and gender) were also collected for analysis. 
 
Image post-processing and analysis  
ADC maps were calculated from diffusion weighted imaging using a linear fit between the 
two b-value images in Matlab (The Mathworks, MA, 2018a). DSC time-course data were 
processed using conventional methods to provide uncorrected cerebral blood volume 
(uCBV) maps, with a leakage correction undertaken to produce corrected cerebral blood 
volume (cCBV) and K2 maps17.  
T2- weighted imaging and ADC maps were registered to the first DSC volume with SPM12 
(UCL). Regions of interest segmenting the tumour volume were drawn on the T2 weighted 
imaging18.  
 
Image analysis was performed in Matlab (2018b, The Mathworks, MA), with the image 
mean, standard deviation, skewness, and kurtosis were calculated on a volume by volume 
basis for ADC and UCBV/CCBV/K2 maps for regions of interest and the whole brain as 
previously described18. Tumour volume (cm3) was calculated from the T2 ROI masks drawn 
by S.W18. Regions of interest were also drawn in normal appearing deep grey and white 
matter for each participant to calculate average diffusion and perfusion measures in normal 
appearing tissue by J.G. Medulloblastoma Chang stage was derived from radiological 
reports. 
 
Histological and Genetic analysis  
Histological (including MiB1, Ki67, Glial fibrillary acidic protein (GFAP), INI-1, Isocitrate 
dehydrogenase-1 (IDH-1), Neuron specific enolase (NSE), S-100, BAF47, BRAF fusions, P53) 
and genetic data (MYC status and medulloblastoma sub-type), where available, were 
collected from local sites and are found in supplementary document 1.  
Medulloblastomas were analysed for histological type, subgroup, and MYC and MYCN 
amplification status were determined by protocols established at Newcastle University19–21 . 
Medulloblastoma histology was centrally reviewed at the Royal Victoria Infirmary. Data are 
summarised in supplementary document 1. 
 
Statistical analysis  
All statistical analyses were performed in R (3.6.1) with significance defined at p<0.05, and 
Bonferroni correction for multiple comparisons used where appropriate.  
The data processing pipeline used in this study is summarised in Figure 1.  
 
Univariate statistical analysis 
Data normality was assessed using a Shapiro-Wilk test. Subsequently, differences in clinical 
and imaging features between high- and low-grade tumours were assessed using unpaired 
t-tests or Mann-Whitney U tests, where appropriate. Area under the ROC curve (AUC) 
values were calculated for each imaging feature for high/low grade discrimination. 
Differences in high-/low- risk (defined below) participants were assessed using unpaired 
two-tailed t-tests or Mann-Whitney U test, depending on data normality.  
 
After unsupervised clustering (described below), further Mann-Whitney U tests were 
performed to assess for differences in imaging features between low grade tumours in low 
and high-risk categories, and between alive high-grade tumours in low- and high-risk 
categories.  
 
Survival and correlation analysis 
Univariate Cox-regression was performed with each individual imaging feature, clinical data, 
and tumour grade used to assess survival hazard coefficients. Tumour grade and type were 
not used in the analysis detailed below.  
Iterative Bayesian survival analysis was undertaken using the iterative BMAsurv package in R 
using 5-fold stratified cross validation to determine the posterior probabilities and 
coefficients of the top 5 imaging features that best describe the survival data22. Iterative 
analysis including up to 15 data features in combination at any one time.  
 
Unsupervised and supervised machine learning 
K means clustering was performed with the imaging features from Bayesian survival 
analysis, with the optimal number of clusters determined from the largest average 
silhouette width. Groups were clustered into high and low risk groups, and subsequently 
used for further Kaplan-Meier analysis to assess for differences in survival between clusters.  
 
Supervised machine learning using the aforementioned Bayesian features was used to 
predict high/low risk groupings using the Orange toolbox (Orange) in Python (3.6), with 
Random Forest, a single layer Neural Network, and a support vector machine used. 
Validation of classifiers was performed using 10-fold stratified cross-validation.  
 
Clinical and imaging data were subset into Whole Brain (WB), and Region of Interest (ROI) 
features, and tumour volume and used for supervised learning. Principal component 
analysis was used to reduce data dimensionality with 95% of data variance or N-1 (where N 
is the size of the smallest group) used. The top 5 Bayesian features were also used as input 
into the classifiers, with no further principal component analysis performed. Classifier 
performance was determined from the classifier accuracy (% correctly classified cases) and 
F-statistic.  
 
  
Results 
A total of 69patients were analysed in this study with 33 imaging features, including tumour 
volume, derived per patient. Example tumour anatomical, diffusion, and perfusion imaging 
can be seen in Figure 2. The survival curve for the whole cohort is seen in Figure 3A, 
showing 75% overall survival. 
 
Diffusion and perfusion imaging can detect differences between tumour grade  
Univariate statistical analysis showed significant differences in both whole brain and ROI 
imaging features between all high and low-grade tumours (feature with highest AUC = ADC 
mean (0.82) range: 0.63-0.82) full results detailed in supplementary Table 2.  Grey and white 
matter imaging results are detailed in supplementary Tables 3.  
 
Perfusion imaging is plays a key role in assessing survival in paediatric brain tumours  
Whole cohort univariate cox regression revealed a number of imaging features with 
significantly elevated hazard ratios (HR), for example Uncorrected CBV ROI mean (HR = 3.1, 
Confidence Intervals (CI) = 1.5-6.6, p = 0.003), full results detailed in Table 1A.   
Bayesian analysis revealed the 5 most likely features to predict survival (probability that the 
feature coefficient is greater than 0, posterior coefficient) to be uCBV ROI mean (96%, 0.85), 
K2 ROI mean (39%, -0.17), uCBV whole brain mean (40%, 0.3), tumour volume (27%, 0.05), 
and ADC ROI kurtosis (20%, 0.02). Full results detailed in Table 1B. 
 
Unsupervised clustering detects distinct groups with significantly different survival and 
imaging characteristics 
Using the Bayesian imaging features, k means clustering revealed two distinct clusters, 
shown in Figure 3B, which when combined with Kaplan-Meier analysis revealed a significant 
difference between a high and low risk population (see Figure 3C, p = 0.0015 – overall 
survival for high and low risk = 55% & 90%, respectively). Cox regression revealed an 
elevated Hazard Ratio (HR = 5.6, confidence intervals = 1.6-20.1, p < 0.001) for the high-risk 
cluster, relative to the low risk cluster.  
Further univariate analysis of each cluster showed significant differences in a number of 
imaging features, for example elevated ADC kurtosis in high vs low risk clusters (10.1 ± 5.3 
vs 4.3 ± 1.8, p<0.001, respectively). A combination of both high- and low-grade tumours 
were found in both clusters, all other results detailed in Table 2. 
 
Supervised machine learning can be used to distinguish between high/low risk clusters 
Supervised machine learning using imaging features showed that the Bayesian features 
combined with a single layer neural network, after stratified 10-fold cross validation, 
provided the most accurate classification of high- and low-risk patients (accuracy = 98%, F-
statistic = 0.98).  
 
There is a distinct difference in survival between high- and low- risk high-grade tumours  
Further Kaplan-Meier analysis of clustered high-grade tumours revealed a significant 
difference in survival (p < 0.05) with a hazard ratio of 7 (0.9-53 lower and upper bounds, 
respectively). The Kaplan-Meier curves for high grade tumours in both clusters can be seen 
in supplementary figure 1. Further to this, it is noted that there are a number of children 
alive at study end with high-risk tumours and  currently limited follow-up, for example a 
Choroid Plexus Carcinoma with a current follow-up of 1 year and a national average 5-year 
survival rate of 26%23 and a medulloblastoma with less than 3-year follow-up and M3 Chang 
stage. There was no detectable difference in survival between the high- and low- risk groups 
within the low grade tumours (p>0.05). Imaging of example cases by risk and grade given in 
Figure 4.  
Qualitative sub-group analysis of histology and genetics between low- and high-risk 
medulloblastomas revealed no significant differences between MYC amplification or 
groupings. The high-risk cluster exhibited a trend toward having a larger number of high 
Chang stage Medulloblastomas (M3 = 6, M2 = 4, M1 = 3) in comparison to the low risk 
cluster (M2 = 1, M1 = 1, M0 = 2) – data shown in supplementary document 1. 
  
Discussion 
 
This study has shown the power of combining diffusion and perfusion imaging with machine 
learning to predict survival risk in a mixed cohort of paediatric brain tumours. A small 
handful of studies have previously looked at assessing survival with one of the 
aforementioned imaging techniques24–26; however, here we have shown the utility of 
combined diffusion-perfusion measures to provide advanced modelling of survival. The 
univariate results assessing low/high grade suggested a number of key diffusion and 
perfusion features for the discrimination between groups, however most had a poor AUC. 
Therefore, this represented an ideal situation for the use of machine learning to combine 
these features to provide highly accurate classifiers to solve this challenge.   
Interestingly, the majority of parameters predicting survival were from the perfusion 
imaging which is not currently part of routine clinical practice in many centres. DWI has 
become a standard method for investigating childhood brain tumours and low ADC is seen 
as being a marker for higher cellularity and grade which would be associated with poorer 
survival. The current study substantiates this but shows that DSC-MRI may be an even 
better modality for predicting survival. The importance of the vessel leakiness parameter K 
in survival prediction also implies that DSC-MRI may have advantages in survival prediction 
beyond that available from methods which do not include the injection of contrast agent 
such as ASL. Furthermore, clustering demonstrated a reasonable separation of high (M1 to 
M3) from low (M0) Chang stage tumours suggesting that these imaging features identify 
some properties in the primary tumour which are associated with metastatic potential. 
 
The unsupervised machine learning identified two groups of tumours which did not 
correspond to any obvious non-imaging tumour characteristics. The credibility of these 
groups as being distinct entities was substantiated by the high accuracy (98%) with which 
the tumours could be assigned to the correct group by a supervised learner. A number of 
patients in the high-risk cluster were still alive at the study end although some of these, 
including those from known poor prognostic groups had short follow-up times.  Further 
analysis showed that a number of surviving high-risk low-grade tumours had imaging 
features similar to high grade tumours (such as elevated ADC kurtosis and CBV) and were 
significantly different to low-risk low grade tumours. It will be interesting to ascertain the 
clinical course of these tumours over longer periods of follow-up. 
 
A particular strength of this work is that imaging features with clinical data provide a non-
invasive tool that can assess risk early in the patient journey. Indeed, the use of a supervised 
classifier to predict risk category allows for the prospective integration of this model into a 
clinical decision support system – whereby radiological analysis of a small number of 
imaging features can rapidly identify patients that should be considered for inclusion into 
clinical trials for prospective evaluation and subsequent stratification. The use of in vivo 
imaging also has the advantage that it provides information that cannot be found from 
analysis of resected tissue, perfusion in particular is inherently an in vivo property.   
A further strength of this study is the use of multi-site, multi-scanner data – providing 
reassurance that the results are robust to the natural variability that occurs in protocols and 
scanners within clinical practice. Using multiple centres also provided a more statistically 
powerful study from which clinically relevant results could be obtained.  
 
The imaging modalities used in this study are widely available and so data acquisition should 
be readily achieved in routine clinical practice. The image processing and  classification 
should be made available by integration into a clinical decision support tool which are 
increasingly being developed27. Indeed, the results shown above show that it is possible to 
stratify patients into high and low risk groups with a trained supervised neural network, 
therefore enabling further real-time decisions to be made with regards to appropriate 
clinical management and inclusion into research trials for novel therapies to aid those with 
the current worst prognosis.  
With the current uncertainty surrounding the use of Gadolinium in clinical practice, and the 
inability to be used in patients with impaired renal function, future work will include the 
addition of arterial spin labelling (ASL), a technique to estimate perfusion without the 
introduction of exogenous contrast agents, as data from this technique has been shown to 
correlate well with DSC cerebral blood volume28,29. However, information on vessel 
leakiness will not be available from ASL. 
 
In conclusion, this work has demonstrated a highly novel clinical application of advanced 
survival modelling and machine learning to non-invasively stratify patients for according to 
risk. Both diffusion and perfusion were found to be important in determining risk with 
perfusion contributing to a greater extent emphasising the importance of acquiring 
perfusion imaging. This work represents an important step forward in the use of machine 
learning to predict survival and paves the way for further clinical studies focusing on the 
successful identification and treatment of high-risk children with brain tumours.  
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Tables 
Table 1 – Cox Regression (A) and Bayesian survival (B) results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 – Low and high-risk cluster group features 
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Figure captions  
Figure 1 – Data processing pipeline used in this study.  
 
 
Figure 2 – Example T2 weighted, diffusion, and perfusion imaging of Ependymoma (A, B, and 
C respectively), Pilocytic astrocytoma (D, E, and F, respectively), choroid plexus carcinoma 
(F, G, and H respectively) and a Glioblastoma (I, J, and K, respectively). 
 
 
Figure 3 – (A) Overall survival curve for the cohort, (B) K Means clustering survival results 
showing two distinct clusters, (C) Kaplan-Meier curve for the two clusters showing a 
significant difference in survival. 1 = High risk, 2 = Low risk 
 
Figure 4 – Example high and low risk, high and low-grade tumors. (A T1 post contrast & B 
ADC map) high risk and (C T1 post contrast & D ADC map) low risk Pilocytic astrocytoma, 
respectively showing elevated ADC skew and kurtosis in the tumor region. (E & F) high risk 
and (G and H) low risk medulloblastomas, respectively, showing increased ADC kurtosis.  
 
 
 
 
 
 
Supplementary figures and tables  
Table S1 - Imaging parameters used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2 - Differences in imaging features between high and low-grade tumors. (A) shows 
region of interest and (B) whole brain results. AUC = area under the curve. 
 
Table S3 - Average gray and white matter diffusion and perfusion values for the brain 
tumor cohort 
 
 
 
 
 
 
 
Figure S1 - Kaplan-Meier curves for high-grade low-risk (red) and high-risk (green) patients 
showing a significant difference in survival from imaging at diagnosis. 
 
